Skip to main content

Table 2 HLA-A24/peptide tetramer analysis

From: Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma

case

Pre-vaccination

After 1st vac.

After 3rd vac.

After 6th vac.

2

0.02/N.D

0.02/N.D

3.05/N.D

N.D

3

0.42/0.02*

0.49/0.02

0.52/0.02

0.62/0.01

4

0.06/0.01

0.41/0.00

0.36/0.01

0.47/0.01

5

0.50/0.06

0.52/0.01

0.09/0.00

0.03/0.02

6

0.02/0.01

0.15/0.01

0.08/0.00

N.D

  1. N.D: not determined, *B peptide tetramer / Control peptide tetramer
  2. HLA-A24/R49.2 pepitde tetramer was used as control in the case 3 patient.
  3. HLA-A24/HIV pepitde tetramer was used as control in the other patients.
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us